Cowen Inc’s Sage Therapeutics SAGE Stock Holding History

Cowen Inc’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-20,000	Closed	-$1.25M	–	343
2017 Q3	$1.25M	Buy	+20,000	New	+$1.57M	0.04%	117
2016 Q3	–	Sell	-7,000	Closed	-$211K	–	258
2016 Q2	$211K	Buy	+7,000	New	+$233K	0.01%	191

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Cowen Inc's SAGE Position: Q4 2017 in Review

Cowen Inc sold out of Sage Therapeutics (SAGE) in Q4 2017, closing a stake of 20,000 shares — an estimated $1.25M sold.

Cowen Inc first reported a position in SAGE in Q2 2016 and held it in 2 quarters. The position peaked at $1.25M in Q3 2017. 224 funds tracked by Wall St. Rank hold SAGE as of Q4 2017.

Cowen Inc reported no remaining Sage Therapeutics position as of Q4 2017 after selling out during the quarter.
Cowen Inc sold 20,000 Sage Therapeutics shares in Q4 2017, an estimated $1.25M.
Cowen Inc first reported a position in Sage Therapeutics in Q2 2016 and held it in 2 quarters.
Cowen Inc's Sage Therapeutics position peaked at $1.25M in Q3 2017.
224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2017.

Based on Cowen Inc's 13F filing for Q4 2017, filed 15 Feb 2018.